EDGE MEDICAL-B (02675) has announced that the overall coordinators, acting for themselves and on behalf of the international underwriters, fully exercised the over-allotment option detailed in the prospectus on Wednesday, February 4, 2026. This involved a total of 4.1583 million H shares, representing approximately 15% of the total number of shares offered under the global offering prior to any exercise of the over-allotment option. The over-allotted shares will be issued and allotted by the Company at an H share price of HK$43.24 per share. These shares will be used to facilitate the accelerated delivery of a portion of H shares to placees who agreed to a delayed delivery of their respective H shares subscribed for under the global offering.
The stabilization period for the global offering concluded on Wednesday, February 4, 2026, which was the 30th day after the deadline for submitting applications under the Hong Kong public offering. The price stabilization actions undertaken during the stabilization period by the stabilization agent, Morgan Stanley Asia Limited, its affiliates, or any person acting on its behalf, are detailed as follows: (1) an over-allotment of a total of 4.1583 million H shares in the international offering, constituting about 15% of the total shares available under the global offering before any over-allotment option was exercised; and (2) the full exercise of the over-allotment option by the overall coordinators on Wednesday, February 4, 2026, for a total of 4.1583 million H shares at HK$43.24 per H share, to expedite the delivery of part of the H shares to placees who had consented to a deferred delivery of their relevant H shares subscribed under the global offering.
Throughout the stabilization period, the stabilization agent did not conduct any market purchases or sales of H shares for the purpose of price stabilization.
Comments